Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making

@article{Dalke2016DepressionAA,
  title={Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making},
  author={Katharine Baratz Dalke and Amy Wenzel and Deborah R. Kim},
  journal={Current Psychiatry Reports},
  year={2016},
  volume={18},
  pages={1-12}
}
Depression and anxiety during pregnancy are common, and patients and providers are faced with complex decisions regarding various treatment modalities. A structured discussion of the risks and benefits of options with the patient and her support team is recommended to facilitate the decision-making process. This clinically focused review, with emphasis on the last 3 years of published study data, evaluates the major risk categories of medication treatments, namely pregnancy loss, physical… 

Effects of depressive and anxiety disorders during pregnancy on gestational age and birth weight: A case-control study

Introduction: Depression and anxiety are the most common psychiatric disorders during pregnancy. Several studies suggest that maternal affective state can negatively affect the fetus, leading to

Anxiety of pregnant women in time of catastrophic events, including COVID-19 pandemic: a systematic review and meta-analysis

Women with complications during pregnancy should be assessed for anxiety independently from catastrophic events, during financial crises, environmental or other disasters, special attention should be given to women with low risk, normal pregnancies.

The Design of Critical Care Information System Supporting Clinical Decision Based on Deep Learning Recognition Method

The deep learning identification method is analyzed in depth and it is shown that the overall performance of the RBM-based method is the best, when the missing degree of the two data sets is 30.6%, the classification accuracy rate is still more than 92.8%.

References

SHOWING 1-10 OF 127 REFERENCES

Risk-benefit decision making for treatment of depression during pregnancy.

A decision-making model designed to structure the information delivered to pregnant women in the context of the risk-benefit discussion is developed, providing structure to a process that is frequently stressful for both patients and psychiatrists.

Patient choice of treatment for postpartum depression: a pilot study

In this small sample of women with PPD, most women chose IPT with or without sertraline, and the suggested predictors of treatment selection identified in this study: previous depression and breastfeeding status.

Relapse of major depression in women who continue or discontinue antidepressant medication during pregnancy.

In both studies, women with at least four previous episodes of depression had a greater risk of relapse of depression during pregnancy, suggesting that those with more severe forms of the disorder are likely at greatest risk for relapse.

Infant Health and Neurodevelopmental Outcomes Following Prenatal Exposure to Duloxetine

Although the present report suggests that duloxetine was not associated with major malformations or neurobehavioural problems, the drug should be used with caution until further information is available on its safety profile in pregnancy.

Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.

Pregnancy is not "protective" with respect to risk of relapse of major depression, and women with histories of depression who are euthymic in the context of ongoing antidepressant therapy should be aware of the association of depressive relapse during pregnancy with antidepressant discontinuation.

Antidepressant use in pregnant and postpartum women.

There is inconclusive evidence of a link between antidepressants in late pregnancy and persistent pulmonary hypertension in the newborn, and extensive study finds that antidepressants cannot be considered major teratogens.

Antipsychotic drugs in pregnancy: a review of their maternal and fetal effects

There is evidence for risks associated with pregnancy and neonatal outcomes and the risk of untreated maternal illness (particularly schizophrenia and bipolar disorder) on both maternal and child outcomes is relevant.

Maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes: a systematic review

An overview of maternal use of antidepressant or anxiolytic medication during pregnancy and childhood neurodevelopmental outcomes is provided and some studies indicate a relation between prenatal exposure to antidepressants and adverse neuro developmental outcomes.
...